单次高剂量维生素D3对中重度COVID-19患者住院时间的影响:一项随机临床试验
这项在巴西圣保罗2个中心开展的多中心、双盲、随机、安慰剂对照试验纳入240例住院中重度COVID-19患者,随机接受单次口服维生素D3 200 000 IU(n=120)或安慰剂(n=120)。主要终点住院时间在维生素D3组与安慰剂组间无显著差异(中位7.0天 vs 7.0天,log-rank P=.59;未校正出院HR 1.07,95%CI 0.82-1.39,P=.62)。住院死亡率(7.6% vs 5.1%,P=.43)、入住ICU(16.0% vs 21.2%,P=.30)、需要有创机械通气(7.6% vs 14.4%,P=.09)均无显著差异;单次给药后25-羟基维生素D平均血清水平显著升高(44.4 ng/mL vs 19.8 ng/mL,差值24.1 ng/mL,95%CI 19.5-28.7,P<.001)。作者结论认为该结果不支持用高剂量维生素D3治疗中重度COVID-19。
要点
- 住院中重度COVID-19患者单次口服维生素D3 200 000 IU与安慰剂相比,住院时间无显著差异(中位7.0天 vs 7.0天,log-rank P=.59)。
- 未校正出院HR为1.07(95%CI 0.82-1.39,P=.62),住院死亡率7.6% vs 5.1%(差值2.5%,95%CI -4.1%至9.2%,P=.43),均无显著差异。
- 入住ICU 16.0% vs 21.2%(差值-5.2%,95%CI -15.1%至4.7%,P=.30),需要有创机械通气7.6% vs 14.4%(差值-6.8%,95%CI -15.1%至1.2%,P=.09),均无显著差异。
- 单次口服维生素D3 200 000 IU后25-羟基维生素D平均血清水平显著高于安慰剂(44.4 ng/mL vs 19.8 ng/mL,差值24.1 ng/mL,95%CI 19.5-28.7,P<.001)。
- 无不良事件报告,但有一次呕吐与干预相关;作者结论认为该结果不支持用高剂量维生素D3治疗中重度COVID-19。
适用人群与场景
- 2020年6月2日至2020年8月27日入组、在巴西圣保罗2个中心住院的中重度COVID-19患者,共240例随机(维生素D3组n=120,安慰剂组n=120),237例纳入主要分析。
- 纳入患者平均(SD)年龄56.2(14.4)岁,女性104例(43.9%),基线25-羟基维生素D平均(SD)水平20.9(9.2)ng/mL。
处置流程与药物剂量
- 单次口服维生素D3 200 000 IU(维生素D3组n=120),对照组口服安慰剂(n=120)。
研究设计与关键结果
- 多中心、双盲、随机、安慰剂对照试验,2个中心,240例随机,237例纳入主要分析;主要终点为住院时间(随机化至出院)。
- 中位(四分位距)住院时间维生素D3组7.0(4.0-10.0)天 vs 安慰剂组7.0(5.0-13.0)天,log-rank P=.59;未校正出院HR 1.07(95%CI 0.82-1.39,P=.62)。
- 住院死亡率维生素D3组7.6% vs 安慰剂组5.1%,差值2.5%(95%CI -4.1%至9.2%),P=.43。
- 入住ICU维生素D3组16.0% vs 安慰剂组21.2%,差值-5.2%(95%CI -15.1%至4.7%),P=.30。
- 需要有创机械通气维生素D3组7.6% vs 安慰剂组14.4%,差值-6.8%(95%CI -15.1%至1.2%),P=.09。
- 单次给药后25-羟基维生素D平均血清水平维生素D3组44.4 ng/mL vs 安慰剂组19.8 ng/mL,差值24.1 ng/mL(95%CI 19.5-28.7),P<.001。
- 无不良事件报告,但有一次呕吐与干预相关。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机、安慰剂对照试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,住院中重度COVID-19患者单次高剂量维生素D3与安慰剂相比未显著缩短住院时间,该结果不支持用高剂量维生素D3治疗中重度COVID-19。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The efficacy of vitamin D3 supplementation in coronavirus disease 2019 (COVID-19) remains unclear.
OBJECTIVE: To investigate the effect of a single high dose of vitamin D3 on hospital length of stay in patients with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, double-blind, randomized, placebo-controlled trial conducted in 2 sites in Sao Paulo, Brazil. The study included 240 hospitalized patients with COVID-19 who were moderately to severely ill at the time of enrollment from June 2, 2020, to August 27, 2020. The final follow-up was on October 7, 2020.
INTERVENTIONS: Patients were randomly assigned to receive a single oral dose of 200 000 IU of vitamin D3 (n = 120) or placebo (n = 120).
MAIN OUTCOMES AND MEASURES: The primary outcome was length of stay, defined as the time from the date of randomization to hospital discharge. Prespecified secondary outcomes included mortality during hospitalization; the number of patients admitted to the intensive care unit; the number of patients who required mechanical ventilation and the duration of mechanical ventilation; and serum levels of 25-hydroxyvitamin D, total calcium, creatinine, and C-reactive protein.
RESULTS: Of 240 randomized patients, 237 were included in the primary analysis (mean [SD] age, 56.2 [14.4] years; 104 [43.9%] women; mean [SD] baseline 25-hydroxyvitamin D level, 20.9 [9.2] ng/mL). Median (interquartile range) length of stay was not significantly different between the vitamin D3 (7.0 [4.0-10.0] days) and placebo groups (7.0 [5.0-13.0] days) (log-rank P = .59; unadjusted hazard ratio for hospital discharge, 1.07 [95% CI, 0.82-1.39]; P = .62). The difference between the vitamin D3 group and the placebo group was not significant for in-hospital mortality (7.6% vs 5.1%; difference, 2.5% [95% CI, -4.1% to 9.2%]; P = .43), admission to the intensive care unit (16.0% vs 21.2%; difference, -5.2% [95% CI, -15.1% to 4.7%]; P = .30), or need for mechanical ventilation (7.6% vs 14.4%; difference, -6.8% [95% CI, -15.1% to 1.2%]; P = .09). Mean serum levels of 25-hydroxyvitamin D significantly increased after a single dose of vitamin D3 vs placebo (44.4 ng/mL vs 19.8 ng/mL; difference, 24.1 ng/mL [95% CI, 19.5-28.7]; P < .001). There were no adverse events, but an episode of vomiting was associated with the intervention.
CONCLUSIONS AND RELEVANCE: Among hospitalized patients with COVID-19, a single high dose of vitamin D3, compared with placebo, did not significantly reduce hospital length of stay. The findings do not support the use of a high dose of vitamin D3 for treatment of moderate to severe COVID-19.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04449718.
参考来源
- Murai IH, Fernandes AL, Sales LP, et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 33595634. doi:10.1001/jama.2020.26848
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。